Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 8:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 142 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Nasogastric Tube Clear all
Completed Phase 2Phase 3 Interventional Results available

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

NCT04603924
View directory record Official record
Conditions
COVID-19
Interventions
Niclosamide, Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Sheffield, Alabama • Irvine, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 2, 2026, 8:54 AM EDT
Terminated Phase 4 Interventional Results available

Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery Patients

NCT02946580
View directory record Official record
Conditions
Constipation
Interventions
MOVANTIK™ (naloxegol), Sugar Pill
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 2, 2026, 8:54 AM EDT
Completed Early Phase 1 Interventional Results available

NAC +taVNS in IDM Who Are Poor Oral Feeders

NCT04632069
View directory record Official record
Conditions
Infant of Diabetic Mother, Oxidative Stress, Vagus Nerve Stimulation, Feeding Disorders
Interventions
N acetyl cysteine + vagus nerve stimulation
Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
3 Weeks to 5 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 2, 2026, 8:54 AM EDT
Terminated Phase 2 Interventional

Nasogastric/Oral Gastric Tube Placement in Infants: Comparing 2 Measurement Methods

NCT01407991
View directory record Official record
Conditions
Enteral Tube Placement
Interventions
enteral tube placement accuracy, NEM method for NG/OG tube placement
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 6 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 2, 2026, 8:54 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Placement of Nasogastric Tubes for Gastric Decompression in Patients With Bronchiolitis

NCT04480970
View directory record Official record
Conditions
Bronchiolitis
Interventions
Nasogastric tube placement
Device
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
1 Day to 23 Months
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 2, 2026, 8:54 AM EDT
Completed Not applicable Interventional

Donor Human Milk in Young Children Receiving Bone Marrow Transplantation

NCT02470104
View directory record Official record
Conditions
Bone Marrow Transplant - Autologous or Allogeneic
Interventions
Breastmilk
Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 4 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 2, 2026, 8:54 AM EDT
Recruiting No phase listed Observational

Phagenyx® Registry Study

NCT06866418
View directory record Official record
Conditions
Dysphagia
Interventions
1. Phagenyx® System Group Patients
Device
Lead sponsor
Phagenesis Ltd.
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
3
States / cities
Phoenix, Arizona • Neptune City, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 2, 2026, 8:54 AM EDT
Completed Phase 4 Interventional

Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial

NCT02462590
View directory record Official record
Conditions
Ventilator Associated Pneumonia, Infections, C-Difficile, Antibiotic-associated Diarrhea, Diarrhea
Interventions
L. rhamnosus GG - Probiotic, Placebo - Microcrystalline Cellulose
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 2, 2026, 8:54 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

NCT04551131
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
Ruxolitinib, Dexamethasone, Etoposide
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Weeks to 22 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 2, 2026, 8:54 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

NCT04467840
View directory record Official record
Conditions
COVID-19, Lung Infection
Interventions
Opaganib, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 2, 2026, 8:54 AM EDT
Recruiting Phase 2 Interventional

MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial

NCT06319248
View directory record Official record
Conditions
Sepsis, Low Blood Pressure
Interventions
Midodrine, Standard of Care
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Mankato, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 2, 2026, 8:54 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone

NCT05582707
View directory record Official record
Conditions
Intracerebral Haemorrhage, Intraventricular
Interventions
Pioglitazone 15mg
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 2, 2026, 8:54 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

NCT03213704
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Larotrectinib Sulfate, Magnetic Resonance Imaging, Radionuclide Imaging, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
122
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 2, 2026, 8:54 AM EDT
Active, not recruiting Phase 1 Interventional

Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder

NCT05818943
View directory record Official record
Conditions
GRIN-related Disorders
Interventions
Radiprodil
Drug
Lead sponsor
GRIN Therapeutics, Inc.
Industry
Eligibility
6 Months to 12 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 2, 2026, 8:54 AM EDT
Not listed Not applicable Interventional

Nasogastric Tube Clamping Trial vs. Immediate Removal

NCT04001985
View directory record Official record
Conditions
Small Bowel Obstruction, Ileus
Interventions
No clamp trial, Clamp trial
Other
Lead sponsor
University of Illinois College of Medicine at Peoria
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 2, 2026, 8:54 AM EDT
Withdrawn Not applicable Interventional

Prospective Study of Non-operative Management of SBO Without Nasogastric Tube Placement

NCT02530086
View directory record Official record
Conditions
Small Bowel Obstruction
Interventions
Nasogastric tube placement, No Nasogastric tube use
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 2, 2026, 8:54 AM EDT
Completed Phase 1 Interventional Results available

Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing

NCT03649932
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia Associated Pulmonary Hypertension, Pulmonary Hypertension, Premature Birth, Chronic Lung Disease of Prematurity
Interventions
Enteral L-citrulline
Dietary Supplement
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 30 Weeks
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 2, 2026, 8:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

NCT04844424
View directory record Official record
Conditions
Healthy
Interventions
Milvexian
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 2, 2026, 8:54 AM EDT
Completed Not applicable Interventional

Efficacy and Safety Study on Nasogastric (NG) Tube in Patients With Upper Gastrointestinal Bleed

NCT00689754
View directory record Official record
Conditions
Gastrointestinal Hemorrhage, Liver Cirrhosis
Interventions
nasogastric tube placement
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2011 · Synced Oct 2, 2026, 8:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants

NCT06211179
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A: Mavacamten intact oral capsule, Treatment B: Mavacamten open capsule in suspension, Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 2, 2026, 8:54 AM EDT
Completed Phase 4 Interventional

Nasogastric Tube Insertion Using Midazolam in the Emergency Department

NCT01375634
View directory record Official record
Conditions
Intubation; Difficult
Interventions
Midazolam
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 2, 2026, 8:54 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Circadian Rhythms in Human Adipose

NCT06891534
View directory record Official record
Conditions
Obesity, Abdominal, Feeding Patterns
Interventions
Continuous Feeding, Intermittent feeding
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 2, 2026, 8:54 AM EDT
Terminated No phase listed Observational

Benefits of Post-Pyloric Feeding Tubes in Critically Ill Patients

NCT01343316
View directory record Official record
Conditions
Critical Illness
Interventions
Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube)
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Oct 2, 2026, 8:54 AM EDT
Completed Not applicable Interventional Results available

Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia

NCT01162499
View directory record Official record
Conditions
Postprandial Hypoglycemia
Interventions
Exendin-(9-39), Vehicle
Drug · Other
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 2, 2026, 8:54 AM EDT